Author: Quiñones-Hinojosa Alfredo Sanai Nader Smith Justin McDermott Michael
Publisher: Springer Publishing Company
ISSN: 0167-594X
Source: Journal of Neuro-Oncology, Vol.74, Iss.1, 2005-08, pp. : 19-30
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Assessment of brain tumor proliferative potential provides important prognostic information that supplements standard histopathologic grading. Many laboratories rely on mitotic figures to quantify the proliferative potential of brain tumors, but this conventional cellular proliferative index is subject to inter-observer variability and not consistently predictive for low-and high-grade tumors. Recent advancements in technology have made it possible to use proliferative indices as a standard supplement in pathology laboratories. Non-invasive tumor tissue measurements of cell proliferation can be performed using– bromodeoxyuridine labeling index (BrdU LI), flow cytometry (FCM), MIB-1 antibody to the Ki-67 antigen (MIB-1), proliferating cell nuclear antigen (PCNA), and argyrophilic nucleolar organizing regions (AgNOR). Each of these assays has been described in the literature with respect to its ability to predict tumor grade or outcome. At the present time MIB-1 and AgNOR are the simplest and most reliable of these techniques. In addition, advances in our understanding of the genetic alterations associated with proliferation promise to provide more specific markers of proliferative potential. Beyond the pathology laboratory, radiographic studies such as positron emission tomography (PET), single photon emission computed tomography (SPECT), and most recently magnetic resonance spectroscopy (MRS) have been
Related content
Cancer Investigation, Vol. 25, Iss. 1, 2007-01 ,pp. :
By Rutka James Kongkham Paul Northcott Paul Carlotti Carlos Guduk Mustafa Osawa Hirokatsu Moreno Orlando Seol Ho Restrepo Andres Weeks Adrienne Nagai Shoichi Smith Christian
Journal of Neuro-Oncology, Vol. 92, Iss. 3, 2009-05 ,pp. :
Neuroendocrine tumors in the brain
Annals of Oncology, Vol. 12, Iss. 2, 2001-02 ,pp. :
Brachytherapy for brain tumors
By Vitaz Todd Warnke Peter Tabar Viviane Gutin Philip
Journal of Neuro-Oncology, Vol. 73, Iss. 1, 2005-05 ,pp. :
Histamine in brain development and tumors
By Panula P. Lintunen M. Karlstedt K.
Seminars in Cancer Biology, Vol. 10, Iss. 1, 2000-02 ,pp. :